AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
RegulatoryapprovedTEPKINLYLenalidomideRituximabPositive
AI Analysis
Summary
AbbVie announced European Commission approval of TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. This regulatory milestone expands the therapeutic options available for this lymphoma indication in Europe.
Outcome Details
European Commission approval for epcoritamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma
Importance:8/10
Sentiment:
0.85
regulatory approvalEuropean Commissiononcologycombination therapyfollicular lymphoma
Related Companies
Read the original article
Published by yahoo_finance on July 6, 2026 5:45 PM